Parkinson’s disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms such as bradykinesia, rigidity, resting tremor, and postural instability. Non-motor symptoms, including sleep disturbances, cognitive impairment, and autonomic dysfunction, further complicate the disease course. The pathophysiology of PD involves the degeneration of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of α-synuclein protein aggregates, forming Lewy bodies. This study aims to assess clinical progression in PD patients and evaluate the correlation between disease duration, symptom severity, and pharmacological response. Data were collected from patients diagnosed with idiopathic PD at three neurology centers across two continents over a 24-month period. The findings suggest significant variability in disease progression and highlight the importance of personalized therapeutic approaches in PD management.

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder globally, affecting approximately 1% of individuals over the age of 60. The disease is primarily caused by the progressive loss of dopaminergic neurons in the substantia nigra, leading to striatal dopamine deficiency. While the cardinal motor features are well known, increasing attention is being paid to the non-motor aspects, which significantly impair quality of life.

The underlying mechanisms of PD are multifactorial, involving oxidative stress, mitochondrial dysfunction, neuroinflammation, and abnormal protein aggregation. Genetic mutations (e.g., SNCA, LRRK2, PARK7) and environmental exposures are also implicated in disease pathogenesis. Despite advances in pharmacotherapy—most notably, the use of Levodopa and dopamine agonists—there remains no cure, and disease-modifying treatments are limited. The present study aims to analyze clinical characteristics and therapeutic response in a diverse cohort of PD patients to better understand disease heterogeneity and inform future treatment strategies.

Study Design and Setting:
This is a longitudinal, observational cohort study conducted across three medical centers in the USA, India, and Spain. The study received ethical clearance from each institution’s review board, and informed consent was obtained from all participants.

Inclusion Criteria:

• Diagnosis of idiopathic Parkinson’s disease according to the UK Parkinson’s Disease Society Brain Bank Criteria
• Age between 45 and 80 years
• Disease duration between 1 and 10 years
• Stable on anti-Parkinsonian medication for at least 3 months prior to enrollment

Exclusion Criteria:

• Atypical or secondary parkinsonism
• Severe cognitive impairment (MMSE < 20>
• History of major psychiatric illness or neurodegenerative disease other than PD

Data Collection:
Participants underwent comprehensive clinical assessments at baseline, 12 months, and 24 months. Evaluations included the Unified Parkinson’s Disease Rating Scale (UPDRS), Hoehn and Yahr staging, Montreal Cognitive Assessment (MoCA), and quality of life questionnaires (PDQ-39). Pharmacological treatment data were also recorded.

Statistical Analysis:
Data were analyzed using SPSS software version 27. Descriptive statistics, paired t-tests, and Pearson correlation coefficients were applied. Statistical significance was set at p < 0>

A total of 146 patients (87 males, 59 females; mean age 65.2 ± 7.4 years) were included. The average disease duration was 4.9 ± 2.1 years. Most patients (72%) were on a combination of Levodopa and dopamine agonists.

At 12 and 24 months, progressive worsening in motor scores (UPDRS Part III) was observed, with an average annual increase of 6.3 points (p < 0 xss=removed>

Patients on early combination therapy showed slower progression compared to those on Levodopa monotherapy, although the difference was not statistically significant (p = 0.08). No significant gender differences were noted in progression rates.

The findings reinforce the heterogeneous nature of Parkinson’s disease. Motor symptoms predictably worsened over time, but the rate of progression varied among individuals. Non-motor symptoms, often underestimated, had substantial impacts on functional status and quality of life. These findings are consistent with prior research emphasizing the multidimensional progression of PD.

Although Levodopa remains the cornerstone of therapy, our observations suggest potential benefit in early combination regimens. The lack of significant gender-based differences supports the idea that PD pathology transcends sex-linked mechanisms, though further research may reveal subtle hormonal or genetic influences.

One limitation of this study is its observational nature and reliance on subjective reporting for non-motor symptoms. Nevertheless, the longitudinal design and multi-center collaboration enhance the validity of our results. Future studies should explore neuroprotective agents and personalized medicine approaches.

Parkinson’s disease continues to present complex clinical challenges, particularly in its unpredictable progression and varied symptomatology. Our study highlights the need for individuality treatment strategies and greater emphasis on non-motor symptom monitoring. As research continues to explore disease-modifying therapies, comprehensive patient-centered management remains crucial to improving outcomes.